Related references
Note: Only part of the references are listed.Isoliensinine: A Natural Compound with Drug-Like Potential
Yan Cheng et al.
FRONTIERS IN PHARMACOLOGY (2021)
A novel FTY720 analogue targets SET-PP2A interaction and inhibits growth of acute myeloid leukemia cells without inducing cardiac toxicity
Carmen Vicente et al.
CANCER LETTERS (2020)
The Function of NM23-H1/NME1 and Its Homologs in Major Processes Linked to Metastasis
Barbara Matyasi et al.
PATHOLOGY & ONCOLOGY RESEARCH (2020)
A new regulatory mechanism of protein phosphatase 2A activity via SET in acute myeloid leukemia
Elena Arriazu et al.
BLOOD CANCER JOURNAL (2020)
Synergic effect of OP449 and FTY720 on oral squamous cell carcinoma
Renata Nishida Goto et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
p53 Function Is Compromised by Inhibitor 2 of Phosphatase 2A in Sonic Hedgehog Medulloblastoma
Yun Wei et al.
MOLECULAR CANCER RESEARCH (2019)
SET protein accumulation prevents cell death in head and neck squamous cell carcinoma through regulation of redox state and autophagy
Amanda Tomie Ouchida et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2019)
Deregulation of SET is Associated with Tumor Progression and Predicts Adverse Outcome in Patients with Early-Stage Colorectal Cancer
Ion Cristobal et al.
JOURNAL OF CLINICAL MEDICINE (2019)
Protocadherin 7 is overexpressed in castration resistant prostate cancer and promotes aberrant MEK and AKT signaling
Gauri Shishodia et al.
PROSTATE (2019)
SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia
Danielle M. Brander et al.
BRITISH JOURNAL OF HAEMATOLOGY (2019)
Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression
Chun-Yu Liu et al.
EBIOMEDICINE (2019)
Identification of PP2A/Set Binding Sites and Design of Interacting Peptides with Potential Clinical Applications
Lu Tian et al.
INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS (2018)
Non-genomic mechanisms of protein phosphatase 2A (PP2A) regulation in cancer
Otto Kauko et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2018)
Antagonizing SET Augments the Effects of Radiation Therapy in Hepatocellular Carcinoma through Reactivation of PP2A-Mediated Akt Downregulation
Chao-Yuan Huang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
Stemness Is Enhanced in Gastric Cancer by a SET/PP2A/E2F1 Axis
Shuhei Enjoji et al.
MOLECULAR CANCER RESEARCH (2018)
A comprehensive and perspective view of oncoprotein SET in cancer
Buuvee Bayarkhangai et al.
CANCER MEDICINE (2018)
SET Overexpression is Associated with Worse Recurrence-Free Survival in Patients with Primary Breast Cancer Receiving Adjuvant Tamoxifen Treatment
Yu-Hsiang Huang et al.
JOURNAL OF CLINICAL MEDICINE (2018)
Mechanisms of transcriptional regulation by p53
Kelly D. Sullivan et al.
CELL DEATH AND DIFFERENTIATION (2018)
PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis
Xiaorong Zhou et al.
CANCER RESEARCH (2017)
SET protein overexpression contributes to paclitaxel resistance in MCF-7/S cells through PI3K/Akt pathway
Weipeng Zhang et al.
JOURNAL OF DRUG TARGETING (2017)
A Comprehensive Review on Chemical Profiling of Nelumbo Nucifera: Potential for Drug Development
Bhesh Raj Sharma et al.
PHYTOTHERAPY RESEARCH (2017)
MYC-dependent recruitment of RUNX1 and GATA2 on the SET oncogene promoter enhances PP2A inactivation in acute myeloid leukemia
Raffaella Pippa et al.
ONCOTARGET (2017)
EGFR-independent Elk1/CIP2A signalling mediates apoptotic effect of an erlotinib derivative TD52 in triple-negative breast cancer cells
Chun-Yu Liu et al.
EUROPEAN JOURNAL OF CANCER (2017)
Overexpression of SET oncoprotein is associated with tumor progression and poor prognosis in human gastric cancer
Xiaoning Yuan et al.
ONCOLOGY REPORTS (2017)
SET contributes to the epithelial-mesenchymal transition of pancreatic cancer
Hardik R. Mody et al.
Oncotarget (2017)
Protein phosphatase 2A regulation of markers of extracellular matrix remodelling in hepatocellular carcinoma cells: functional consequences for tumour invasion
M. P. Ward et al.
BRITISH JOURNAL OF PHARMACOLOGY (2017)
AKT/PKB Signaling: Navigating the Network
Brendan D. Manning et al.
CELL (2017)
Potential Role for Inhibition of Protein Phosphatase 2A Tumor Suppressor in Salivary Gland Malignancies
Johannes Routila et al.
GENES CHROMOSOMES & CANCER (2016)
SET antagonist enhances the chemosensitivity of non-small cell lung cancer cells by reactivating protein phosphatase 2A
Man-Hsin Hung et al.
ONCOTARGET (2016)
Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode
Donglai Wang et al.
NATURE (2016)
Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential
M-H Hung et al.
ONCOGENE (2016)
Isoliensinine induces dephosphorylation of NF-λB p65 subunit at Ser536 via a PP2A-dependent mechanism in hepatocellular carcinoma cells: roles of impairing PP2A/I2PP2A interaction
Guangwen Shu et al.
ONCOTARGET (2016)
Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia
Nameeta P. Richard et al.
ONCOTARGET (2016)
CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia
Eva Barragan et al.
HAEMATOLOGICA (2015)
Isoliensinine, a Bioactive Alkaloid Derived from Embryos of Nelumbo nucifera, Induces Hepatocellular Carcinoma Cell Apoptosis through Suppression of NF-κB Signaling
Guangwen Shu et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2015)
Eviction of linker histone H1 by NAP-family histone chaperones enhances activated transcription
Qian Zhang et al.
EPIGENETICS & CHROMATIN (2015)
Overexpression of PP2A inhibitor SET oncoprotein is associated with tumor progression and poor prognosis in human non-small cell lung cancer
Hao Liu et al.
ONCOTARGET (2015)
Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia
Shuzhen Wang et al.
ONCOTARGET (2015)
Inhibition of Pten deficient Castration Resistant Prostate Cancer by Targeting of the SET-PP2A Signaling axis
Xiaoyong Hu et al.
SCIENTIFIC REPORTS (2015)
A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation
Guang Yang et al.
CELL REPORTS (2015)
CIP2A high expression is a poor prognostic factor in normal karyotype acute myeloid leukemia
Eva Barragan et al.
HAEMATOLOGICA (2015)
Deregulation of the PP2A Inhibitor SET Shows Promising Therapeutic Implications and Determines Poor Clinical Outcome in Patients with Metastatic Colorectal Cancer
Ion Cristobal et al.
CLINICAL CANCER RESEARCH (2015)
Inhibition of Ku70 acetylation by INHAT subunit SET/TAF-Iβ regulates Ku70-mediated DNA damage response
Kee-Beom Kim et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2014)
SET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cell
Hao Liu et al.
CELLULAR SIGNALLING (2014)
67-kDa Laminin Receptor-dependent Protein Phosphatase 2A (PP2A) Activation Elicits Melanoma-specific Antitumor Activity Overcoming Drug Resistance
Shuntaro Tsukamoto et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Stable SET knockdown in head and neck squamous cell carcinoma promotes cell invasion and the mesenchymal-like phenotype in vitro, as well as necrosis, cisplatin sensitivity and lymph node metastasis in xenograft tumor models
Lays M. Sobral et al.
MOLECULAR CANCER (2014)
Targeting Inhibitors of the Tumor Suppressor PP2A for the Treatment of Pancreatic Cancer
Amy S. Farrell et al.
MOLECULAR CANCER RESEARCH (2014)
Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer
Mahnaz Janghorban et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Antagonistic activities of the immunomodulator and PP2A-activating drug FTY720 (Fingolimod, Gilenya) in Jak2-driven hematologic malignancies
Joshua J. Oaks et al.
BLOOD (2013)
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis
Sahar A. Saddoughi et al.
EMBO MOLECULAR MEDICINE (2013)
PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells
Paolo Neviani et al.
JOURNAL OF CLINICAL INVESTIGATION (2013)
Ser9 phosphorylation causes cytoplasmic detention of I2PP2A/SET in Alzheimer disease
Guang Yu et al.
NEUROBIOLOGY OF AGING (2013)
Ceramide-orchestrated signalling in cancer cells
Samy A. F. Morad et al.
NATURE REVIEWS CANCER (2013)
Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling
M. Danielle Bareford et al.
CANCER BIOLOGY & THERAPY (2012)
Overexpression of SET is a recurrent event associated with poor outcome and contributes to protein phosphatase 2A inhibition in acute myeloid leukemia
Ion Cristobal et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
SET protein accumulates in HNSCC and contributes to cell survival: Antioxidant defense, Akt phosphorylation and AVOs acidification
Andreia M. Leopoldino et al.
ORAL ONCOLOGY (2012)
Mechanism of inhibition of PP2A activity and abnormal hyperphosphorylation of tau by I2PP2A/SET
Lisette Arnaud et al.
FEBS LETTERS (2011)
Apolipoprotein E and Peptide Mimetics Modulate Inflammation by Binding the SET Protein and Activating Protein Phosphatase 2A
Dale J. Christensen et al.
JOURNAL OF IMMUNOLOGY (2011)
Targeting SET/I2PP2A oncoprotein functions as a multi-pathway strategy for cancer therapy
C. H. Switzer et al.
ONCOGENE (2011)
Fingolimod (FTY720): First approved oral therapy for multiple sclerosis
Sushil Sharma et al.
JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS (2011)
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Jeffrey A. Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling
Archana Mukhopadhyay et al.
FASEB JOURNAL (2009)
OPINION Is NF-κB a good target for cancer therapy? Hopes and pitfalls
Veronique Baud et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Characterization of Ser338 Phosphorylation for Raf-1 Activation
Mengwei Zang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55α regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt
Yi-Chun Kuo et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia
Paolo Neviani et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
GSK-3β acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 in ceramide-induced mitochondrial apoptosis
Chiou-Feng Lin et al.
JOURNAL OF CELL SCIENCE (2007)
Relationship between the structure of SET/TAF-Iβ/INHAT and its histone chaperone activity
Shinsuke Muto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Protein kinase A activates protein phosphatase 2A by phosphorylation of the B56δ subunit
Jung-Hyuck Ahn et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Rac1-induced cell migration requires membrane recruitment of the nuclear oncogene SET
Jean Paul ten Klooster et al.
EMBO JOURNAL (2007)
Involvement of I2PP2A in the abnormal hyperphosphorylation of tau and its reversal by Memantine
Muhammad Omar Chohan et al.
FEBS LETTERS (2006)
Positive regulation of Raf1-MEK1/2-ERK1/2 signaling by protein serine/threonine phosphatase 2A holoenzymes
DG Adams et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein
P Neviani et al.
CANCER CELL (2005)
Kinomics: methods for deciphering the kinome
SA Johnson et al.
NATURE METHODS (2005)
The histone chaperone TAF-I/SET/INHAT is required for transcription in vitro of chromatin templates
MJ Gamble et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
The life cycle of C-myc - From synthesis to degradation
RC Sears
CELL CYCLE (2004)
Type-2A protein phosphatase activity is required to maintain death receptor responsiveness
AS Härmälä-Braskén et al.
ONCOGENE (2003)
Tumor suppressor NM23-H1 is a granzyme A-activated DNase during CTL-mediated apoptosis, and the nucleosome assembly protein SET is its inhibitor
ZS Fan et al.
CELL (2003)
Regulation of histone acetylation and transcription by INHAT, a human cellular complex containing the set oncoprotein
SB Seo et al.
CELL (2001)
Functional interaction between nucleosome assembly proteins and p300/CREB-binding protein family coactivators
N Shikama et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Type 2A protein phosphatase, the complex regulator of numerous signaling pathways
S Zolnierowicz
BIOCHEMICAL PHARMACOLOGY (2000)
Share Paper
